Differences of the Fecal Microflora With Clostridium difficile Therapies | Zendy

Thomas Louie | Zendy; Brendan Byrne | Zendy; J.C. Herbert Emery | Zendy; Linda Ward | Zendy; W. Krulicki | Zendy; D.T. Nguyen | Zendy; Kaiyu Wu | Zendy; Kristine Can | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Differences of the Fecal Microflora With Clostridium difficile Therapies

Author(s) -

Thomas Louie,

Brendan Byrne,

J.C. Herbert Emery,

Linda Ward,

W. Krulicki,

D.T. Nguyen,

Kaiyu Wu,

Kristine Can

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ252

Subject(s) - clostridium difficile , metronidazole , microbiome , microbiology and biotechnology , feces , medicine , vancomycin , clostridium difficile toxin a , enterococcus , pathogen , lactobacillus , clostridium , antibiotics , biology , bacteria , staphylococcus aureus , bioinformatics , genetics

During treatment of Clostridium difficile infection (CDI), patterns of pathogen reduction in relationship to changes in components of the normal microbiota are hypothesized to be predictive of response to treatment and subsequent sustained cure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research